Katarzyna (Kasia) A. Rejniak (PI)
Shari Pilon-Thomas (PI), Moffitt
Michael Poch (PI), Moffitt
Mehdi Damaghi (PI), Stony Brooks
*Project immuno-Oncology in bladder cancer
The adoptive immunotherapy with intravesical
delivery of autologous tumor-infiltrating T lymphocytes (TIL) has the
potential to improve clinical outcomes in patients with bladder cancer.
The adoptive immunotherapy has three main phases:
|
We will (1) develop and validate an in silico model to enhance T cell infiltration into the bladder tumor; (2) predict in silico and validate in PDX models the methods to enhance T cell functionality; (3) optimize and validate combination schedules of adoptive T cell therapy in teh bladder cancer. |
The first step in upstaging of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) is manifested as microinvasions, that is cohorts of cells that breach the basement membrane and penetrate into the surrounding tissue. Our goal is to test whether emergence of reactive stroma is a pre-requisite for initiation of microinvasions and involves metabolic reprogramming of stromal cells.
We will develop an integrated computational-experimental approach to (i) stratify the impact of tumor-derived metabolic conditions on stromal activation; (ii) assess the role of reactive stroma in promoting microinvasions in DCIS; and (iii) evaluate reactive stroma signatures in DCIS histology. |